Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Germany | Italy | Jordan | Korea | Mexico | Morocco | Poland | Portugal | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Università degli Studi di Brescia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Macular Edema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2100047726 | N/A |
Completed |
Pterygium |
2020-12-31 |
|
ChiCTR1900021312 | N/A |
Recruiting |
Cataract |
2019-01-31 |
|
OHSV | N/A |
Unknown status |
Keratitis, Herpetic|Herpes Simplex |
2018-03-01 |
|
Oral001 | N/A |
Completed |
Macular Degeneration |
2016-12-31 |